Navarra – February 2024 – Medibiofarma S.L., a clinical-stage biotechnology company developing a portfolio of new therapies for the treatment of neurodegenerative diseases and other pathologies announced the first patient dosed in the Phase IIa clinical trial of MBF-015 in patients with...